Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGXSWX:PPGN +0.23%80 EV-to-EBIT is 57.45 as of Aug. 16, 2026, which is 486% above its 10-year median of 9.81. GuruFocus rates XSWX:PPGN with a GF Score™ of 80/100 and a GF Value™ of CHF34.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 684 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 86.11% on this metric.
PolyPeptide Group AG (XSWX:PPGN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PolyPeptide Group AG's Enterprise Value for the quarter that ended in Jun. 2026 was CHF1,626.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF26.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG EV-to-EBIT Related Terms
PolyPeptide Group AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:PPGN vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's EV-to-EBIT falls into.
PolyPeptide Group AG's current Enterprise Value is CHF1,531.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF26.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (XSWX:PPGN) has a EV-to-EBIT of 57.45 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PolyPeptide Group AG and its competitors. This is 486% above median its historical median of 9.81. According to the industry distribution chart, PolyPeptide Group AG ranks #589 out of 684 companies in the Drug Manufacturers industry, placing it in the top 86.1%.
Is PolyPeptide Group AG's EV-to-EBIT too high?
PolyPeptide Group AG's current EV-to-EBIT of 57.45 is 486% above median its 10-year median of 9.81. The Drug Manufacturers industry median EV-to-EBIT is 15.99. PolyPeptide Group AG's value of 57.45 is 259.3% above this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #589 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PolyPeptide Group AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #589 out of 684 companies for EV-to-EBIT. This places PolyPeptide Group AG in the lower half of its industry. The industry median EV-to-EBIT is 15.99. PolyPeptide Group AG's value of 57.45 is 259.3% above this benchmark. While the company's 10-year median is 9.81 vs. the industry median of 15.99, PolyPeptide Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current EV-to-EBIT of 57.45 is 259.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current EV-to-EBIT is 57.45, which is 486% above median its own 10-year median of 9.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF34.68, compared to a current price of CHF44.10 — trading 27.2% above its estimated fair value. The current EV-to-EBIT is 57.45, which is 486% above median its 10-year median of 9.81 and 259.3% above the Drug Manufacturers industry median of 15.99. PolyPeptide Group AG's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current EV-to-EBIT is 57.45 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of CHF44.10 is trading 27.2% above its estimated GF Value™ of CHF34.68.
GuruFocus considers PolyPeptide Group AG to be Modestly Overvalued.
Key valuation signals for XSWX:PPGN:
EV-to-EBIT: 57.45 (486% above median its 10-year median of 9.81)
GF Value™: CHF34.68 vs. price of CHF44.10 (27.2% above fair value)
Industry Position: 259.3% above the Drug Manufacturers median (#589 of 684)
No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
80GF Score
Get the complete analysis for XSWX:PPGN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PPGN has been successfully added to your 
